Resverlogix Corp RVXCF:OTCPK

RT Quote | Exchange | USD
Last | 02/26/21 EST
0.749quote price arrow down-0.031 (-3.9744%)
Volume
10,000
52 week range
0.42 - 1.12

...

Loading . . .

KEY STATS

  • Open0.7568
  • Day High0.7568
  • Day Low0.749
  • Prev Close0.78
  • 52 Week High1.12
  • 52 Week High Date09/29/20
  • 52 Week Low0.42
  • 52 Week Low Date06/08/20
  • Market Cap170.44M
  • Shares Out233.99M
  • 10 Day Average Volume13,881.09
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-16.78

RATIOS/PROFITABILITY

  • EPS (TTM)0.02
  • P/E (TTM)45.59
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Resverlogix Corp News

There is no recent news for this security.

Latest RVXCF News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of...
Donald McCaffrey
Chairman
A. Brad Cann
Chief Financial Officer
Address
300-4820 Richard Rd SW
Calgary, AB
T3E 6L1
Canada